Trial Profile
A multicenter, double-blind, randomized, active controlled study to compare the effect of 52 weeks treatment with vildagliptin 50 mg bid to pioglitazone 30 mg daily as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Vildagliptin (Primary) ; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 01 Jan 2008 Status change from active, no longer recruiting to completed
- 18 Oct 2006 Status change from recruiting to active, no longer recruiting.
- 01 Sep 2006 The expected completion date for this trial is now 20 Jul 2007.